Al-Haddad Afaf, Alarami Nada, Alshammari Abdullah F, Madfa Ahmad A
Department of Conservative Dentistry, Faculty of Dentistry, Sana'a University, Sana'a, Yemen.
Department of Conservative Dentistry, Royal Phoenix Clinic Dubai, Dubai, United Arab Emirates.
BMC Oral Health. 2025 Jun 3;25(1):899. doi: 10.1186/s12903-025-06288-5.
The objective of this systematic review was to evaluate the effectiveness of home and professional single-application desensitizers that contain bioactive glass in comparison to other desensitizing methods and agents or negative controls in randomized controlled trials.
Two reviewers searched the electronic databases Cochrane Central Library, PubMed, Scopus, and Web of Science using specific keywords. The randomized controlled clinical trials (RCTs) that focused on the use of bioactive glass-based desensitizers to treat dentin hypersensitivity (DH) through December 2024 were included. Data extraction, selection, and screening were completed. Descriptive analyses were conducted, and the Critical Appraisal Skills Programme (CASP) and updated Cochrane tools were used to evaluate the quality assessment and risk of bias, respectively.
A total of 30 studies were involved in this evaluation, and all of them were assessed as low risk of bias except one that had some concerns. Pain responses of 2845 patients with an age range of 17-75 years were assessed in this review. The efficacy of bioactive glass-based desensitizers in reducing sensitivity pain was superior compared to baseline and to various desensitizing agents and placebo. The follow-up assessment time was varied, and accordingly, the long-term efficacy of bioactive glass was similar to other agents.
With the limitation of this review, the bioactive-glass-based desensitizing agent used in-office or at home is effective to reduce DH response in the immediate, medium, or long term up to 12 weeks. The efficacy of this agent is comparable to most of the available desensitizers in the long term; however, it is more effective in the immediate to medium term, up to 4 weeks.
本系统评价的目的是在随机对照试验中，评估含生物活性玻璃的家用和专业单次应用脱敏剂与其他脱敏方法、试剂或阴性对照相比的有效性。
两名评价者使用特定关键词检索电子数据库Cochrane中央图书馆、PubMed、Scopus和Web of Science。纳入截至2024年12月聚焦于使用基于生物活性玻璃的脱敏剂治疗牙本质过敏症（DH）的随机对照临床试验（RCT）。完成数据提取、选择和筛选。进行描述性分析，并分别使用批判性评估技能计划（CASP）和更新后的Cochrane工具评估质量评估和偏倚风险。
本评价共纳入30项研究，除一项存在一些问题外，所有研究的偏倚风险均被评估为低风险。本评价评估了年龄在17 - 75岁的2845例患者的疼痛反应。与基线、各种脱敏剂和安慰剂相比，基于生物活性玻璃的脱敏剂在减轻敏感疼痛方面的疗效更佳。随访评估时间各不相同，因此，生物活性玻璃的长期疗效与其他试剂相似。
受本评价的局限性影响，在诊所或家中使用的基于生物活性玻璃的脱敏剂在即刻、中期或长达12周的长期内均能有效减轻DH反应。该试剂的疗效在长期内与大多数现有脱敏剂相当；然而，在即刻至中期（长达4周）更为有效。
